Previous 10 | Next 10 |
Diamond Offshore Drilling (NYSE: DO ) -35% after skipping interest payment. More news on: Diamond Offshore Drilling, Inc., Athersys, Inc., InVivo Therapeutics Holdings Corp., Stocks on the move, , Read more ...
Athersys (NASDAQ: ATHX ) has priced its public offering of 22.25M common stock at $2.25/share, for gross proceeds of ~$50.1M. More news on: Athersys, Inc., Healthcare stocks news, , Read more ...
Athersys, Inc. (NASDAQ: ATHX) (Athersys) today announced the pricing of its previously announced underwritten public offering of its common stock, par value $0.001 per share (Common Stock), at a price to the public of $2.25 per share, for a total of 22,250,000 shares. Gross proceeds to At...
Athersys, Inc. (NASDAQ: ATHX) (Athersys) announced today that it intends to offer for sale $50 million of shares of its common stock, par value $0.001 per share (Common Stock), in an underwritten public offering. In addition, Athersys expects to grant the underwriters a 30-day option to purch...
Phase 2 study of cell therapy in trauma expands Company’s clinical programs focused on critical care Athersys, Inc. (NASDAQ: ATHX) announced today that the U.S. Food and Drug Administration (FDA) has authorized an Investigational New Drug (IND) application to initiate a P...
SCWorx (NASDAQ: WORX ) +171% on order for 2M COVID-19 blood tests. More news on: SCWorx Corp., Can-Fite BioPharma Ltd., Independence Contract Drilling, Inc., Stocks on the move, , Read more ...
In a Phase 1/2 study of MultiStem therapy for the treatment of ARDS, favorable tolerability data and meaningful potential benefits in mortality, ventilator-free days and ICU-free days observed Company plans to initiate a Phase 2/3 pivotal study in patients with COVID-19 induced ARDS th...
In this follow up to our original bearish article on Athersys (ATHX), we address the two main counterpoints that we have received through comments and messages on Seeking Alpha. We believe these criticisms miss the mark and the evidence that we presented in our article is what is relevant....
Company Overview Athersys Incorporated (Ticker: ATHX ) is a biotechnology company that is focused primarily in the field of regenerative medicine and is committed to the discovery and development of best-in-class therapies designed to extend and enhance the quality of human life. ATHX h...
Capricor Therapeutics (NASDAQ: CAPR ) +26% on providing its CAP-1002 cell therapy under compassionate use for patients with advanced COVID-19. More news on: Capricor Therapeutics, Inc., Fate Therapeutics, Inc., SAExploration Holdings, Inc., Stocks on the move, Read m...
News, Short Squeeze, Breakout and More Instantly...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to ra...